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Abstract. Endometrial cancer (EC) is the sixth most common 
cancer in women worldwide. Early diagnosis is critical in 
recurrent EC management. The present study aimed to iden-
tify biomarkers of EC early recurrence using a workflow that 
combined text and data mining databases (DisGeNET, Gene 
Expression Omnibus), a prioritization algorithm to select a set 
of putative candidates (ToppGene), protein-protein interaction 
network analyses (Search Tool for the Retrieval of Interacting 
Genes, cytoHubba), association analysis of selected genes 
with clinicopathological parameters, and survival analysis 
(Kaplan-Meier and Cox proportional hazard ratio analyses) 
using a The Cancer Genome Atlas cohort. A total of 10 genes 
were identified, among which the targeting protein for Xklp2 
(TPX2) was the most promising independent prognostic 
biomarker in stage I EC. TPX2 expression (mRNA and 
protein) was higher (P<0.0001 and P<0.001, respectively) in 
ETS variant transcription factor 5-overexpressing Hec1a and 
Ishikawa cells, a previously reported cell model of aggressive 
stage I EC. In EC biopsies, TPX2 mRNA expression levels 
were higher (P<0.05) in high grade tumors (grade 3) compared 
with grade 1-2 tumors (P<0.05), in tumors with deep myome-
trial invasion (>50% compared with <50%; P<0.01), and in 
intermediate-high recurrence risk tumors compared with 
low-risk tumors (P<0.05). Further validation studies in larger 
and independent EC cohorts will contribute to confirm the 
prognostic value of TPX2.
Introduction
Endometrial cancer (EC) is the sixth most common cancer 
in women worldwide and the second most common gyne-
cologic neoplasm after cervical cancer. According to 
IARC/GLOBOCAN data (1), a worldwide increase of 52.7% 
in incidence and 70.6% in mortality is expected in EC for the 
year 2040.
According to its histopathological characteristics, EC is 
classified in two categories: Type I or endometrioid endo-
metrial carcinomas (EEC), and type II or non-endometrioid 
endometrial carcinomas (NEEC) (2). EEC is the most frequent 
histological type (~80% of all cases); when diagnosed at an 
early stage [stage I, according to the classification of the 
International Federation of Gynecology and Obstetrics 
(FIGO), 2009] (3) and low histological grade, it is associated 
with a good prognosis and 5-year survival rates of 90% (4,5). 
However, 13-25% of patients with EEC suffer recurrence 
and metastatic disease, which is associated with a poor 
outcome (6-10).
The lower survival rates of patients with relapsed stage I 
EEC depend on disease distribution. It has been reported that 
5-year survival is reduced to 55% for pelvic recurrences and to 
17% for extra-pelvic recurrences (11). Notably, patients diag-
nosed with advanced disease (stage III/IV) have a high risk of 
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recurrence and are more likely to have extra-pelvic metastases 
at the time of recurrence (12).
Early diagnosis is critical in recurrent EC management. 
In this context, despite the benefits of the FIGO 2009 
surgical-pathological staging system (3), some limitations 
have been reported. In particular, in Stage I EC, an inaccurate 
prognostic assessment may lead to unnecessary follow-up for 
the majority of patients or to suboptimal treatment of patients 
who will eventually suffer relapse.
The challenge to improve current EC decision-making and 
management has involved deepening the understanding of the 
molecular basis of EC, in order to identify molecular entities 
with altered expression and/or functions, known as biomarkers. 
In recent decades, a number of tissue biomarkers have been 
introduced for EC prognosis (13,14). In addition, several studies 
have proposed EC molecular prognostic signatures (15-17). In 
particular, the use of high-throughput sequencing technology 
coupled with bioinformatics has led to a comprehensive 
genetic and molecular characterization of EC by The Cancer 
Genome Atlas (TCGA) research network (18). As part of 
this characterization, four EC molecular subtypes have been 
identified with distinctive molecular and clinicopathological 
features (DNA polymerase ε, microsatellite instability, copy 
number (CN) Low and CN High) (18). Despite its power as a 
prognostic tool, TCGA classification involves evaluations with 
a set of techniques (genomics, transcriptomics, proteomics 
and somatic CN alterations assessment) that require great 
professional expertise and sophisticated equipment, and thus 
elevated costs, making its implementation difficult in clinical 
services worldwide.
To gain further insight into EC biology and the identification 
of prognostic biomarkers, the present study was conducted to 
search for differentially expressed genes (DEGs) in EC tissues. 
These genes were prioritized after comparison with a refer-
ence list of EC-related genes gathered from the DisGeNET 
database. Subsequently, the prioritized genes were subjected 
to further hierarchical clustering analysis in a different EC 
cohort. Then, an enrichment analysis of DEGs with infor-
mation from pathway and/or Gene Ontology databases was 
performed. In addition, an evaluation was carried out to assess 
whether DEG-encoded proteins physically interact within the 
cell or are part of protein molecular networks. A set of genes 
were further subjected to association analysis with EC clini-
copathological parameters and survival analysis. Finally, an 
expression analysis of one candidate biomarker was conducted 
using a cell model of EC aggressiveness and a pilot validation 




Survey of EC‑associated genes. To survey current knowledge 
on EC-related genes, the DisGeNET gene-disease associations 
database was used (19,20). DisGeNET version 5.0 (online 
version), containing >500,000 associations between >17,000 
genes and 20,000 diseases, was used for this study. DisGeNET 
uses a vocabulary for diseases given by the Concept Unique 
Identifiers from the Unified Medical Language System® 
(UMLS) Metathesaurus® (version UMLS 2018AA) (21). 
Specifically, genes associated with the following EC disease 
terms were collected: ‘Endometrial neoplasms’, ‘Endometrial 
carcinoma’, ‘Stage endometrial cancer’, ‘Recurrent endome-
trial cancer’, ‘Serous endometrial intraepithelial carcinoma’, 
‘Endometrial Squamous Cell Carcinoma’, ‘Endometrial 
endometrioid adenocarcinoma’, ‘Endometrial intraepithelial 
neoplasia’, ‘Endometrial serous adenocarcinoma’, ‘Endometrial 
adenocarcinoma’, ‘Endometrial stromal sarcoma’, ‘Low grade 
endometrial stromal sarcoma’, ‘Endometrial stromal tumors’ 
and ‘Malignant neoplasm of endometrium’. To obtain a 
complete repertoire of EC-associated genes, a search including 
all identified terms referring to EC was performed and results 
were compiled in one list.
Analysis of EC DEGs. Affymetrix microarray data from 
the GSE17025 dataset [n=103 samples; control (atrophic 
endometrium), n=12; tumor, n=91] (22), was obtained from 
the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/) database. The clinicopathological character-
istics of the patients included in this cohort are detailed in 
Table SI. Microarray data were analyzed using GPL570 
platform (Affymetrix Human Genome U133 Plus 2.0 Array; 
Affymetrix; Thermo Fisher Scientific, Inc.). DEGs between 
non‑tumor and tumor samples were identified using GEO2R 
(https://www.ncbi.nlm.nih.gov/geo/geo2r/), where genes with 
adjusted P<0.05 and |log[fold‑change (FC)]|>0.5 were defined 
as DEGs. Multiple testing corrections were performed through 
Benjamini-Hochberg False Discovery Rate (FDR)<0.05. In 
addition, RNAseq (Illumina GA platform; Illumina, Inc.) 
and clinical data from TCGA Uterine Corpus Endometrioid 
Cancer (UCEC; n=333 samples; mean age, 63.2 years; age 
range, 33-90 years; Table SII) dataset was retrieved from the 
UCSC Xena portal (https://xena.ucsc.edu) in order to address 
the prognostic potential of EC candidate genes.
Gene prioritization. Gene prioritization and functional 
enrichment [Gene Ontology (GO) and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways] analyses of DEGs 
were performed using ToppGene Suite (http://toppgene.
cchmc.org) (23). ToppGene Suite is a portal that allows 
functional enrichment, prioritization of candidate genes 
using functional annotations and/or analysis of interaction 
networks, leading to identification of disease candidate genes. 
Gene prioritization analysis was carried out considering the 
following parameters: GO (molecular function, biological 
process and cellular component), Human phenotype, Mouse 
phenotype, Pathway, Pubmed, Interaction, Co-expression, 
Co-expression Atlas and Disease. In all cases, the standard 
method used to determine statistical significance (P<0.05) 
was the Hypergeometric probability distribution with 
Benjamini-Hochberg FDR correction.
Identification of DEGs among tumors of histological grade 1 
and 3. To identify a subset of DEGs among tumors of histo-
logical grade 1 and 3 among the 3,976 prioritized genes 
using TCGA UCEC RNAseq data, the unpaired Student's 
t-test between subjects assuming equal variances was applied 
(P<0.01). To define sample and gene clusters, non‑supervised 
hierarchical clustering was performed. For all these analyses 
the MeV software (http://mev.tm4.org/) was used. Functional 
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enrichment analysis of each gene cluster was performed 
in ENRICHR (http://amp.pharm.mssm.edu/Enrichr/). The 
ggplot2 R (https://github.com/tidyverse/ggplot2) package was 
used to create heatmap plots.
Protein‑protein interaction (PPI) network analysis 
construction. A PPI network was built using the Search Tool 
for the Retrieval of Interacting Genes (STRING) database 
(https://string-db.org/). In addition, identification of hub 
genes was conducted using the cytoHubba application in 
Cytoscape (24).
In silico analysis of TPX2 post‑translational modifications. 
Prediction of the content of potential glycosylation (N and 
O‑glycosylation), as well as phosphorylation sites in the TPX2 
protein sequence (NP_036244.2) was performed. For this 
purpose, glycosylation sites were predicted using the NetNGlyc 
1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/) and 
the NetOGlyc 4.0 Server (http://www.cbs.dtu.dk/services/
NetOGlyc/) (N and O-glycosylation sites, respectively), and 
putative phosphorylation sites were predicted using the NetPhos 
3.1 Server (http://www.cbs.dtu.dk/services/NetPhos/).
Experimental approaches
Patient samples. Endometrial tissue samples were obtained 
from patients with EC who underwent surgery before receiving 
hormonal and/or chemotherapy treatment at Vall d'Hebron 
Hospital (Barcelona, Spain) between January 2006 and 
December 2015 (mean age, 66.5 years; age range, 40-82 years). 
The Institutional Review Boards from Vall d'Hebron Hospital 
and from IBYME approved the protocol, and written informed 
consent was provided by all patients participating in the study 
(approval no. SAF-20083997; CE001/2013). Samples were 
classified based on the 2009 FIGO staging system. Sample 
collection and handling was done as previously described (25). 
Table SIII shows patient samples clinical information.
Cell culture. Hec1a and Ishikawa EC commercial cell lines, 
as well as Hec1a and Ishikawa cells stably transfected with 
the human ETS variant transcription factor 5 (ETV5) sequence 
(Hec1a-ETV5 and Ishikawa-ETV5, respectively) were kindly 
provided by Dr Reventos and co-workers (Biomedical 
Research Group in Gynecology at Vall d'Hebron Research 
Institute, Barcelona, Spain). ETV5‑overexpressing Hec1a and 
Ishikawa cells were generated by stable transfection with the 
pEGFP-C2 vector (BD Biosciences) containing the human 
ETV5 coding sequence, as previously reported (26). Hec1a 
and Hec1a-ETV5 cells were cultured in McCoy's 5A, while 
parental and ETV5-transfected Ishikawa cells were cultured in 
DMEM:F12, all supplemented with 10% fetal bovine serum, 
and handled as described (26). Cell lines were morphologi-
cally and genetically authenticated and tested for mycoplasma 
in accordance with American Association for Cancer 
Research guidelines as previously reported (27). The mRNA 
expression levels of ETV5 were monitored in Hec1a, Ishikawa, 
Hec1a-ETV5 and Ishikawa-ETV5 cells, by means of reverse 
transcription-quantitative PCR (RT-qPCR) (Fig. S1).
RNA extraction, cDNA synthesis and qPCR. Procedures were 
performed as previously reported (28). Briefly, total RNA was 
extracted from cell lines and tissue samples with TRIzol® 
(Invitrogen; Thermo Fisher Scientific, Inc.), according to 
standard protocols. cDNA synthesis was performed with 
1-2 µg total RNA using the SuperScript™ III reverse tran-
scriptase enzyme at 50˚C (Thermo Fisher Scientific, Inc.). 
Negative controls omitting RNA or reverse transcriptase 
were included and tested in the PCR procedure. Quantitative 
evaluation of mRNA levels was performed by qPCR using 
SYBR-Green® PCR Master Mix (Thermo Fisher Scientific, 
Inc.) with the CFX96 Touch™ unit (Bio‑Rad Laboratories, 
Inc.). Thermocycling conditions were as follows: Stage 1, 
2 min at 50˚C; stage 2, 10 min at 95˚C; stage 3, 15 sec at 95˚C; 
stage 4, 1 min at 60˚C; stages 3‑4 were repeated 40 times. 
All samples were run in triplicate; negative controls (the two 
aforementioned controls of the RT assay and a PCR control 
where the DNA template was omitted) were tested in all cases. 
Transcript expression levels were determined as follows: 
2-ΔCq, where: DCq=Cq gene under study-Cq housekeeping 
gene (GAPDH) (29). PCR primers sequences were as follows: 
Targeting protein for Xklp2 (TPX2), forward 5'-GCG CTC 
TGA TTG GTG CAT TC-3', reverse 5'-TTC TTC CCA CGG CTC 
ACC TA-3' (PCR fragment size, 131 bp); GAPDH, forward 
5'-TGC ACC ACC AAC TGC TTA GC-3' and reverse 5'-GGC 
ATG GAC TGT GGT CAT GAG-3' (PCR fragment size, 88 bp); 
ETV5, forward 5'-TGC TTC AGC TAA CCA AGC CT-3', reverse 
5'-ATG GTC CCA GGG AAA TCT CG-3' (PCR fragment size, 
150 bp).
Fluorescence immunocytochemistry. Cell monolayers were 
fixed with 4% paraformaldehyde for 10 min, treated with 0.1% 
Triton X‑100 for 10 min and blocked with 4% bovine serum 
albumin (Sigma-Aldrich; Merck KGaA) in PBS for 45 min; 
all of these procedures were performed at room tempera-
ture. Subsequently, cells were incubated for 1 h at 37˚C with 
2 µg/ml anti‑TPX2 antibody (1:50; mouse monoclonal, 
epitope mapping amino acids 635-675 near C-terminus; 
cat. no. sc-376812; Santa Cruz Biotechnologies, Inc.), followed 
by a 1‑h incubation at room temperature with a fluorescent 
secondary antibody (1:500; goat anti-mouse IgG-Cy3 conju-
gate; cat. no. A10521; Invitrogen; Thermo Fisher Scientific, 
Inc.). Negative controls were run using the same concentration 
of purified IgG (cat. no. I5381; Sigma‑Aldrich; Merck KGaA) 
from the same species as the primary antibody. Nuclear cell 
staining was done with Hoechst 33342 (Sigma-Aldrich; Merck 
KGaA). Cell preparations were analyzed using a Nikon C1 
confocal laser microscope (Nikon Corporation).
Sample preparation, SDS‑PAGE and western immunoblotting. 
Cell lysates were prepared in RIPA buffer [20 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate] 
supplemented with a cocktail of protease inhibitors (2 mM 
p-aminobenzamidine, 1 mM PMSF, 10 µg/ml aprotinin and 
10 µg/ml leupeptin). Protein concentration was determined 
using the Bradford method (Bio-Rad Laboratories, Inc.). 
Protein extracts (30 µg) from EC cell lines were separated by 
SDS-PAGE on 10% gels and were electrotransferred to nitrocel-
lulose membranes (Amersham Hybond ECL; GE Healthcare). 
Membranes were blocked in PBS containing 5% nonfat milk 
for 1 h at room temperature incubated overnight at 4˚C with 
2 µg/ml anti‑TPX2 antibody (1:100; cat. no. sc‑376812; Santa 
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Cruz Biotechnology, Inc.) diluted in blocking solution, and for 
1 h at room temperature with secondary antibody [horseradish 
peroxidase (HRP)-conjugated anti-mouse IgGs; 1:1,000; cat. 
no. 32430; Thermo Fisher Scientific, Inc.] in blocking solution. 
Assays were developed with ECL Western Blotting Detection 
kit (GE Healthcare) chemiluminescence system. Negative 
controls run using the same concentration of purified IgG from 
the same species as the primary antibody were included in all 
cases.
Statistical analysis. In order to determine whether the data 
followed a Gaussian distribution, the D'Agostino-Pearson test 
was used. Comparisons involving two groups of samples were 
analyzed using unpaired Student's t-test or Mann-Whitney 
test, as shown in each case. For studies involving more than 
two experimental groups, the Kruskal Wallis test followed by 
Dunn's post hoc test was applied.
To define gene expression cut-off values, the Cutoff 
Finder web tool (http://molpath.charite.de/cutoff/) (30) was 
used (method ‘survival’), and subsequent analysis between 
categorical variables was performed using the Fisher's Exact 
Test. Specifically, samples were classified, according to the 
expression level of each gene included in the analysis, as ‘low’ 
or ‘high’ expression categories, according to the cut-off value 
determined by applying the ‘survival’ method in Cutoff Finder. 
In addition, Receiver Operating Characteristic (ROC) curves 
were used to determine diagnostic accuracy of selected genes.
For survival analysis, Kaplan-Meier curves were constructed 
and the differences between them were analyzed by the log-rank 
test. Additionally, Cox proportional hazards model was used 
to identify independent survival predictor variables. Analyses 
were performed on GraphPad Prism version 5 (GraphPad 
Software, Inc.) and R (version 3.4.4; http://www.r-project.org/). 
The workflow used in the present study is shown in Fig. 1.
Results
Survey of EC‑associated genes using the DisGeNET 
database. A search on DisGeNET was conducted using 
different EC-related terms to obtain a spectrum of genes 
associated with EC. The scientific literature shows incon-
sistencies regarding the terms used when reporting findings, 
and terms are sometimes not the same to describe a specific 
phenomenon or variable studied. Consequently, the different 
source databases that are integrated into DisGeNET annotate 
the genes associated with EC to different terms present in 
the controlled vocabularies. While only 10 genes were found 
to be associated to the disease term ‘endometrial cancer 
recurrent’, a higher number of genes with potential prognostic 
significance in EC have been described in the literature, and 
several of these genes have not been annotated to the term 
‘endometrial cancer recurrent’. The spectrum of disease terms 
related to EC was expanded to retrieve all of the associated 
genes that could have potential prognostic value in EC. All of 
these genes were surveyed and compiled in a list. A total of 
930 EC-associated genes are listed in Table SIV.
Analysis of EC‑DEGs and gene prioritization. Microarray 
data from the GSE17025 study (GEO repository) was used to 
identify DEGs between non-tumoral atrophic endometria from 
postmenopausal women and tumor endometrial samples with 
the GEO2R tool, resulting in a total of 6,945 DEGs (P<0.05). In 
order to prioritize these genes according to their relevance for 
the EC phenotype, the ToppGene tool was used. Specifically, a 
comparison was done between the list of EC-associated genes 
retrieved from the DisGeNET database (‘training set’) and the 
gene list gathered from the GSE17025 dataset (‘test set’). As 
a result, a list of 3,976 genes associated with the disease was 
obtained (P<0.05) (data not shown).
Gene expression profiles of candidate genes. To determine 
the relevance of genes identified in the gene prioritization 
analysis, their gene expression profiles were evaluated using 
RNAseq data from TCGA UCEC study. Gene expression 
profiles of the prioritized genes were analyzed only in tumor 
Figure 1. Workflow diagram of text and data mining tools used for the 
identification of prognostic EC biomarkers. Genes associated with the entire 
repertoire of EC-related disease terms were gathered from DisGeNET in 
order to cover a higher spectrum of genes with potential prognostic value in 
EC. These genes were used as a reference for further selection and prioriti-
zation of EC-DEGs retrieved from the GEO microarray dataset GSE17025. 
The prioritized genes were then subjected to hierarchical clustering analysis 
using TGCA UCEC RNAseq dataset, which led to the identification of a set 
of DEGs able to generate sample and gene clusters. Since sample cluster 
segregation has a lack of prognostic significance, gene clusters were further 
analyzed. To determine if DEGs belonged to the same pathways, enrichment 
analysis and PPI network analysis were carried out. A set of ‘hub genes’ were 
identified, and statistical association analysis with EC clinicopathological 
parameters and survival analysis was performed. Finally, pilot validation 
studies were performed using EC cell models and tissue specimens. EC, 
endometrial cancer; DEGs, differentially expressed genes; GEO, Gene 
Expression Omnibus; TCGA, The Cancer Genome Atlas; UCEC, Uterine 
Corpus Endometrioid Cancer; PPI, protein-protein interaction.
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samples (n=333). Considering that histological grade has 
been reported to have a significant impact on recurrence‑free 
survival (RFS) in patients with stage I EC (31), the expression 
profile of the prioritized genes in tumor tissues was evalu-
ated according to histological grades 1 and 3 (Student's t-test; 
P<0.05). First, four clusters were identified among tumor 
samples, clusters 1 (n=41), 2 (n=86), 3 (n=102) and 4 (n=104) 
(Fig. 2A). A significant association was found between the 
number of samples in each cluster and tumor histology, 
stage, grade and molecular subtype (Table SV). Cluster 4 
depicted the highest number of serous carcinomas, as well as 
the highest number of advanced stage (III and IV), grade 3 
and CN High subtype carcinomas, although only 13.46 % 
(14/104) cases showed all four negative prognostic factors. 
Clusters 1‑4 were associated with a significant segregation 
of endometrial tumors according to their clinicopathological 
characteristics. However, this segregation was not related 
to EC patient prognosis, since no significant differences 
were observed in RFS and overall survival (OS) curves in 
the cohort studied (RFS, P=0.2465; OS, P=0.6361; Fig. S2). 
However, the comparison of DEGs between grade 1 and 
grade 3 tumors revealed the segregation of three distinc-
tive gene clusters (clusters I, II and III; Fig. 2A). Clusters 
I and II (448 and 293 genes, respectively) contained genes 
with increased expression in grade 3 tumors compared with 
grade 1 tumors, whereas cluster III (189 genes) contained 
genes with a diminished expression in grade 3 tumors 
compared with grade 1 tumors. Functional enrichment 
analysis of the genes included in each cluster indicated that 
genes from clusters I and II were mainly associated with cell 
cycle regulation, whereas genes from cluster III were related 
to protein metabolism and regulation of translation (Fig. 2B). 
Table I lists the most representative functional annotations of 
each cluster.
PPI network analysis and identification of hub genes. In order 
to evaluate the interactions between DEGs obtained as a result 
of the comparison between grade 1 and 3 EC, a PPI network 
was constructed using the STRING database. The resulting 
network contained a total of 930 nodes and 9,392 edges. 
Subsequently, the network hub genes were identified using 
the cytoHubba application in Cytoscape. The top 10 genes 
with the highest degree of connectivity were defined as the 
hub genes: CCNB2, CDCA8, CDC20, CDK1, CENPF, KIF2C, 
RRM2, UBE2C, TOP2A and TPX2 (Fig. 3; Table II). Since 
these genes were also differentially expressed between EC 
and control samples, to determine their diagnostic potential, a 
ROC curve analysis was performed using RNAseq data from 
TCGA UCEC cohort. As a result, all hub genes significantly 
distinguished patients with EC from control patients (CCNB2, 
AUC=0.9834; CDCA8, AUC=0.9832; CDC20, AUC=0.9885; 
CDK1, AUC=0.9486; CENPF, AUC=0.9727; KIF2C, 
AUC=0.9807; RRM2, AUC=0.9720; UBE2C, AUC=0.9762; 
TOP2A, AUC=0.9640; TPX2, AUC=0.9775; P<0.0001 for 
all genes; Fig. S3). Subsequently, the association between 
the expression levels of hub genes and clinicopathological 
parameters was evaluated. Firstly, a higher expression of all 
hub genes was confirmed in grade 3 compared with grade 1‑2 
tumors. Moreover, CCNB2, CDCA8, CDC20, CENPF, KIF2C, 
UBE2C, TOP2A and TPX2 expression was significantly 
associated with tumor histology, with highest mRNA levels 
in NEEC cases. In addition, CDCA8, CDK1, CENPF, UBE2C 
and TPX2 transcript levels were higher in stage III-IV than in 
stage I-II tumors. Finally, CDCA8, CDK1, UBE2C and TPX2 
expression levels were higher in tumors with deep myometrial 
invasion (MI) (Table III).
Next, the relationship between expression of the 10 hub 
genes and prognosis of patients with EC was assessed in TCGA 
cohort. A higher expression of CDK1, KIF2C, UBE2C and 
Figure 2. Hierarchical clustering of grade 1 and 3 EC samples. (A) Differential gene expression analysis between grade 1 and 3 EC tumors generated four 
sample clusters (clusters 1‑4) and three gene clusters (clusters I‑III). Heatmap representation of the top 100 significant genes of each gene cluster is shown. 
(B) Functional enrichment analysis of gene clusters showing most significantly represented biological processes for each gene cluster. EC, endometrial cancer.
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Table I. Functional enrichment analysis of gene clusters I-III.
A, Cluster I
GO term Adjusted P-value Genes
Cell Cycle_Homo sapiens_ 9.9122x10-22 TOP2A; AHCTF1; HSP90AB1; ZWILCH; MCM10; RSF1; SMC4; 
R-HSA-1640170  CDC20; NIPBL; CDC23; EXO1; NUF2; NEK2; KNTC1; YWHAG; 
  RAB2A; HUS1; KIF23; TERF1; MASTL; SMC1A; CKAP5; YWHAZ; 
  CDC25A; PSMA6; TFDP1; PSMA1; NUP50; PSME4; UBE2V2; DNA2; 
  MAPRE1; PSMD12; SEH1L; PSMD11; PSMD14; PKMYT1; CENPA; 
  SKA2; CCNB2; BRIP1; PSMB2; RBBP4; RAD21; E2F3; BUB3; CENPW; 
  RRM2; UBE2C; GINS4; NUP153; TPX2; CENPF; PSMC1; PSMC2; 
  CDK1; TUBGCP3; RAD1; LPIN2; NUP37
Cell Cycle, Mitotic_ 2.4984x10-19 TOP2A; AHCTF1; HSP90AB1; ZWILCH; MCM10; SMC4; CDC20; 
Homo sapiens_  NIPBL; CDC23; NUF2; NEK2; KNTC1; YWHAG; RAB2A; KIF23; 
R-HSA-69278  MASTL; SMC1A; CKAP5; CDC25A; PSMA6; TFDP1; PSMA1; NUP50; 
  PSME4; DNA2; MAPRE1; PSMD12; SEH1L; PSMD11; PSMD14; 
  PKMYT1; CENPA; SKA2; CCNB2; PSMB2; RBBP4; RAD21; E2F3; 
  BUB3; RRM2; UBE2C; GINS4; NUP153; TPX2; CENPF; PSMC1; 
  PSMC2; CDK1; TUBGCP3; CENPO; LPIN2; NUP37
M Phase_Homo sapiens_ 1.7904x10-16 AHCTF1; PSMD12; PSMD11; SEH1L; PSMD14; ZWILCH; SMC4; 
R-HSA-68886  CENPA; SKA2; CDC20; CCNB2; NIPBL; CDC23; PSMB2; RAD21; 
  NUF2; KNTC1; BUB3; RAB2A; UBE2C; NUP153; KIF23; MASTL; 
  SMC1A; CKAP5; PSMA6; CENPF; PSMA1; PSMC1; NUP50; PSMC2; 
  PSME4; CDK1; CENPO; MAPRE1; LPIN2; NUP37
Gene Expression_ 1.7904x10-16 ZNF496; TDRKH; GSK3B; SMG1; HNRNPU; ZC3H8; ADAR; EPRS;  
Homo sapiens_  GLS; MED14; MED13; CASP10; EXO1; XPO5; RIOK1; YWHAG; ZIK1; 
R-HSA-74160  SUPT16H; TBP; PDPK1; NCBP2; HUS1; BAZ1B; YWHAZ; SRRM1; 
  SAP30; PSMA6; TFDP1; PSMA1; XRN1; TBL1XR1; NUP50; PSME4; 
  TET3; RRAGD; POLR1E; DNA2; FYTTD1; ZNF274; PSMD12; SEH1L; 
  PSMD11; RBM8A; PSMD14; RPN2; DDX21; TARS; BAZ2A; RNPC3; 
  GTF2E1; BRIP1; MED30; PDCD11; PSMB2; RBBP4; PLAGL1; TRA2B; 
  BMS1; ZKSCAN3; EIF4H; TP53BP2; IARS2; RPP14; EXOSC3; SKIL; 
  EIF4B; POLR2K; DCAF13; ZNF420; WWTR1; WTAP; CBX3; UTP3; 
  TAF11; CDC5L; NUP153; LSM4; GATAD2B; LSM3; TPX2; PHF5A; 
  NR6A1; EIF5; POLR3B; PSMC1; PSMC2; CDK1; TAF4B; RAD1; 
  CDK12; DCP1A; TAF2; RAN; FARSB; NUP37; EIF4G1
Separation of Sister 3.424x10-16 PSMD12; AHCTF1; PSMD11; SEH1L; PSMD14; ZWILCH; CENPA; 
Chromatids_  SKA2; CDC20; CDC23; PSMB2; RAD21; NUF2; KNTC1; BUB3; 
Homo sapiens_  UBE2C; SMC1A; CKAP5; PSMA6; CENPF; PSMA1; PSMC1; PSMC2; 
R-HSA-2467813  PSME4; CENPO; MAPRE1; NUP37
B, Cluster II
GO term Adjusted P-value Genes
Cell Cycle_Homo sapiens_ 0.00026303 DIDO1; ANKLE2; YWHAB; CDCA5; CDCA8; FOXM1; PSMA7; 
R-HSA-1640170  LMNA; E2F1; NUP88; PSMF1; PCNT; CSNK2A1; NCAPH2; TUBB; 
  TOP3A; RANGAP1; LEMD2; POLA2; PSMC4; DKC1; MCM3; MCM4; 
  KIF2C; SPC24; LPIN3
Cell Cycle, Mitotic_ 0.00061651 ANKLE2; CSNK2A1; NCAPH2; CDCA5; TUBB; CDCA8; FOXM1; 
Homo sapiens_  RANGAP1; LEMD2; PSMA7; POLA2; PSMC4; LMNA; MCM3; E2F1;
R-HSA-69278  MCM4; NUP88; KIF2C; PSMF1; PCNT; SPC24; LPIN3
Axon guidance_ 0.00231835 BRAP; EPHB6; ROBO3; CSNK2A1; YWHAB; LIMK1; ARAF; FN1; 
Homo sapiens_  PHB; PSMA7; DNM2; ARPC2; PSMC4; CFL1; GRB2; PSMF1; COL9A2; 
R-HSA-422475  JAK3; EPHB1; SPTAN1; MYH10; CAMK2G
M Phase_Homo sapiens_ 0.00231835 ANKLE2; CSNK2A1; NCAPH2; CDCA5; CDCA8; RANGAP1; LEMD2; 
R-HSA-68886  PSMA7; PSMC4; LMNA; NUP88; KIF2C; PSMF1; SPC24; LPIN3
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TPX2 was significantly associated with shorter OS (Fig. 4A), 
whereas no associations were found for the other hub genes 
(data not shown). Moreover, CCNB2, CDCA8, CDC20, CDK1, 
KIF2C, RRM2, UBE2C and TPX2 were significantly associ-
ated with RFS (Fig. 4B). No association was found between 
CENPF and TOP2A genes and RFS (data not shown).
Cox proportional hazards regression analysis was performed 
using histology, FIGO stage, grade, MI and expression of the 
10 hub genes (data not shown). As a result, histology, grade 
and MI were the only independent OS predictors (histology: 
P=0.027, hazard ratio: 1.824; grade: P=0.042, hazard ratio: 
2.062; MI: P<0.0001, hazard ratio: 3.729). On the other hand, 
stage, grade and UB2C were the only RFS predictors (stage: 
P<0.0001, hazard ratio: 2.571; grade: P=0.0055, hazard ratio: 
1.730; UB2C: P=0.005, hazard ratio: 1.955). A similar analysis 
done for stage I tumors identified UB2C, TPX2, KIF2C and 
MI as only OS predictors (UB2C: P=0.025, hazard ratio: 0.187; 
TPX2: P=0.066, hazard ratio: 3.776; KIF2C: P=0.013, hazard 
ratio: 5.647; MI: P<0.0001, hazard ratio: 5.748). In the case 
of RFS, TPX2, KIF2C and histology were the only predictors 
(TPX2: P=0.014, hazard ratio: 3.557; KIF2C: P=0.047, hazard 
ratio: 2.659; histology: P=0.091, hazard ratio: 0.388).
TPX2 expression analysis in EC cell models and patient 
samples. Since TPX2 was identified as the best independent 
RFS predictor in stage I EC, a set of experiments was performed 
to assess its expression in EC cell models and patient samples.
Firstly, TPX2 mRNA and protein expression analysis 
was conducted in EC cell models depicting different degrees 
of aggressiveness. For this purpose, Hec1a and Ishikawa 
parental cells and ETV5 stable transfectants of both cell lines 
(Hec1a-ETV5 and Ishikawa-ETV5, respectively) were evalu-
ated. As a result, an increase of 20-25 times in TPX2 transcript 
expression was detected in cells overexpressing ETV5 
compared with parental cells (Fig. 5A). In agreement with these 
results, an increased expression of TPX2 protein was detected 
by western blotting (Fig. 5B) and fluorescence immunocyto-
chemistry (Fig. 5C) in Hec1a-ETV5 and Ishikawa-ETV5 when 
compared with Hec1a and Ishikawa cells, respectively.
Next, TPX2 mRNA levels were determined in EC tissue 
biopsies. Firstly, grade 3 tumor samples exhibited higher TPX2 
levels than grade 1‑2 tumors (Fig. 5D; P<0.05), confirming 
results from the in silico analysis (Fig. 3; Table II). In addition, 
a higher expression of TPX2 was detected in samples with 
deep MI (Fig. 5E; P<0.01). Finally, TPX2 mRNA levels were 
Table I. Continued.
B, Cluster II
GO term Adjusted P-value Genes
Immune System_ 0.00274532 DCTN5; CUL7; YWHAB; MAPKAP1; ARAF; ICAM5; PHB; UBE2Z; 
Homo sapiens_  ECSIT; UBE2J2; ELK1; PLD3; PSMA7; ICAM1; ADCY5; RNF216; 
R-HSA-168256  IRAK1; CFL1; KIF5A; ATP6V0A2; NUP88; PSMF1; JAK3; SPTAN1; 
  CAMK2G; POLR2L; CTSA; BRAP; IL11RA; LIMK1; FN1; DNM2; 
  MAVS; ARPC2; TRIM39; PSMC4; TRAF3; POLR3E; GRB2; UBA1; 
  KIF2C; CRK; RAPGEF3; ATP6V1B1
C, Cluster III
GO term Adjusted P-value Genes
Metabolism of proteins_ 4.165x10-6 TSTA3; COX19; ARF1; L3MBTL2; DCTN1; RPL31; POMT1; PARN;  
Homo sapiens_  PIGV; ZDHHC2; RPS14; POFUT2; EXOSC4; RPL18A; FBXO4; RPL15; 
R-HSA-392499  EXTL3; RPS10; MPDU1; PIAS4; SEC16B; NFYC; H3F3A; DYNC1LI2; 
  RPS28; CCNE2; EEF1D; EIF3G; PDCL; EXOC3; RPL29; PFDN5
Eukaryotic Translation 0.00039761 RPS14; RPS28; RPL18A; EEF1D; RPL31; RPL15RPL29; RPS10
Elongation_Homo sapiens_  
R-HSA-156842  
Selenocysteine synthesis_ 0.00039761 RPS14; RPS28; RPL18A; RPL31; SECISBP2; RPL15; RPL29; RPS10
Homo sapiens_  
R-HSA-2408557  
Formation of a pool of free 0.00052927 RPS14; RPS28; RPL18A; RPL31; EIF3G; RPL15; RPL29; RPS10
40S subunits_Homo  
sapiens_R-HSA-72689  
Infectious disease_Homo 0.0005955 ARF1; RPL31; GTF2F1; RPS14; RPS28; CDK7; PSMB5; PSMC3; 
sapiens_R-HSA-5663205  RPL18A; RPL15; RPL29; RPS10; VPS28; AP1M1
GO, Gene Ontology.
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higher in intermediate-high recurrence risk tumors compared 
with low risk tumors, classified following guidelines previ-
ously established (32) (Fig. 5F; P<0.05).
Discussion
EC risk stratification is currently performed using clinicopath-
ological data (stage, grade, MI and lymphovascular invasion), 
which are not always representative of the tumor biology (32) 
and show discrepancies in the final diagnosis (33-35). 
Therefore, there is a need to identify EC biomarkers that 
contribute to the prediction of the early evolution of tumors, 
particularly in stage I tumors that may relapse, with the aim 
to optimize preoperative disease management and follow-up.
Considering the relevance that bioinformatics has 
gained in translational medicine, several algorithms have 
been implemented in recent years for the identification of 
biomarkers with prognostic value in several types of cancer. 
As an example, gene expression profile analysis performed 
using genomic and clinical data stored in public repositories 
has led to the identification of biomarkers with potential 
prognostic value in prostate (36) and breast (37) cancer, 
among others.
DisGeNET has been used in several studies, including for 
a survey analysis of disease-associated genes (38), prediction 
of associations between diseases and genes and non-coding 
sequences (39,40), and associations between diseases (41,42). In 
the present study, DisGeNET analysis quickly and systemati-
cally yielded a total of 930 EC-related genes. This set of genes 
was used as a ‘training set’ in ToppGene analysis to prioritize 
the 6,945 EC DEGs retrieved from GEO. Using TCGA UCEC 
cohort, gene expression profile analysis of the prioritized 
genes (3,976 genes) identified 930 DEGs in tumors according 
to histological grade, a clinicopathological parameter signifi-
cantly associated with EC relapse (31). Gene expression profiles 
revealed three distinctive gene clusters, with genes upregulated 
(clusters I and II) or downregulated (cluster III) in grade 3 
tumors in comparison to grade 1 tumors. These results are in 
line with a recent study reporting the identification of genes and 
microRNAs (miRs) differentially expressed in grade 3 EC and 
functionally associated with cell cycle regulation (43).
To determine whether the resulting DEGs were associated 
with a common cellular pathway, two approaches were used. 
First, an enrichment analysis of DEGs with information from 
pathway databases and/or the GO was done. A second approach 
aimed at evaluating whether DEG-encoded proteins may phys-
ically interact within the cell or are part of protein molecular 
networks. These two approaches are complementary; current 
pathway-curated databases do not capture all the genes in 
the human genome and consequently several DEGs may not 
be annotated to any pathway in these databases. The human 
interactome map has a higher coverage on proteins encoded by 
human genes; therefore, it can provide additional insights than 
those based only on pathway databases. Moreover, PPI networks 
have been used to infer candidate genes for different types of 
cancer (44-48). These networks are sensitive to disruption 
of high degree proteins (proteins with numerous interaction 
partners, also named hub genes) (49,50) since protein degree 
correlates with its gene essentiality for phenotype survival. 
PPI network analysis using the STRING database in combina-
tion with the cytoHubba application led to the identification 
of the following hub genes: CCNB2, CDCA8, CDC20, CDK1, 
CENPF, KIF2C, RRM2, UBE2C, TOP2A and TPX2.
From the ROC curve analysis, it was revealed that all hub 
genes significantly distinguished EC from control patients, 
suggesting their diagnostic potential. Further evaluations 
strengthen the relevance of the identified hub genes in EC, as 
evidenced by the significant associations found between their 
expression and tumor grade, stage, histology and MI. Finally, 
the survival analysis revealed a negative impact of an increased 
expression of some hub genes on OS and RFS. Among them, 
TPX2 was found as an independent negative prognostic 
predictor of RFS and OS in stage I tumors. In line with these 
observations, increased TPX2 expression (mRNA and protein) 
was detected in Hec1a and Ishikawa human endometrial adeno-
carcinoma cell lines overexpressing ETV5. This transcription 
factor has been found to be overexpressed in EEC tissues, 
particularly in stage IB tumors (51). Moreover, a higher ETV5 
expression has been detected at the invasive front of EC tissues 
when compared with matched‑superficial tumor areas, and has 
been found to serve a role in MI. In line with these findings, 
previous studies revealed epithelial to mesenchymal transition 
molecular changes, as well as a more migratory and invasive 
phenotype in Hec1a and Ishikawa cells overexpressing ETV5 
than parental cell lines (52); since they have been proposed 
as a model of early stage EC aggressiveness, these cell lines 
were considered useful for the present study. In line with these 
findings, TPX2 transcript levels were higher in endometrial 
tumors with features associated with intermediate-high risk of 
recurrence. It is worth noting that Ishikawa‑ETV5 cells TPX2 
Western blot analysis revealed the presence of two protein 
forms. In this regard, a bioinformatics analysis identified 
four potential N-glycosylation sites (NetNGlyc 1.0 Server), 75 
potential O‑glycosylation sites (NetOGlyc 4.0 Server) and ≥50 
potential phosphorylation sites (NetPhos 3.1 Server) for TPX2 
(data not shown). Regarding the latter, evidence of TPX2 
phosphorylation has been reported (53,54).
TPX2 is a key factor for the assembly of the mitotic spindle 
and of microtubules during apoptosis. It activates Aurora 
kinase A during mitosis and directs its activity to the mitotic 
spindle, serving an important role in mitosis. In recent years, 
Figure 3. Protein-protein interaction network analysis of grade 1 and 3 differ-
entially expressed genes. Network hub genes identified using the cytoHubba 
application in Cytoscape. Ten hub genes with the highest degree of connec-
tivity were identified: CCNB2, CDCA8, CDC20, CDK1, CENPF, KIF2C, 
RRM2, UBE2C, TOP2A and TPX2.
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it has been shown that both proteins can generate a functional 
unit with oncogenic properties (55). Increased expression of 
TPX2 has been associated with the progression of different 
types of cancer (56). Recent studies have linked TPX2 
expression with EC; in particular, two bioinformatics studies 
have related TPX2 with EC pathogenesis (57,58). In addition, 
TPX2 was identified as a target of miR‑29a‑5p, following a 
mechanism that would regulate EC cell proliferation, invasion 
and apoptosis (59). In line with these findings, the Aurora 
kinase gene has been recently identified as one of 13 principal 
genes involved in the carcinogenesis of poorly differentiated 
endometrial tumors (60).
Studies based on bioinformatics approaches may have 
some limitations, mainly due to incomplete knowledge of 
protein interaction maps in humans, although it has already 
been demonstrated that even with this incomplete knowledge, 
it is possible to gain insight on disease-associated modules (61). 
In addition, they may bias the knowledge on genes associated 
with diseases, since for many human diseases, the complete 
catalog of genes and sequence variants is not available, and 
the information is scattered across different databases and 
the literature. Moreover, different databases have their own 
annotation criteria with regards to the use of controlled 
vocabularies and ontologies. Furthermore, the information 
Table II. Functional enrichment analysis of hub genes.
A, Biological process (GO)
Term/pathway Description False discovery rate
GO:1903047 Mitotic cell cycle process 2.92x10-13 
GO:0051301 Cell division 8.13x10-12 
GO:0000280 Nuclear division 1.59x10-7 
GO:0140014 Mitotic nuclear division 3.70x10-7 
GO:0051726 Regulation of cell cycle 3.82x10-7 
B, Molecular function (GO)
Term/pathway Description False discovery rate
GO:0008022 Protein C-terminus binding 0.0122 
GO:0005524 ATP binding 0.0122 
GO:0004693 Cyclin-dependent protein serine/threonine kinase activity 0.0122 
GO:0042826 Histone deacetylase binding 0.0153 
GO:0003682 Chromatin binding 0.0153 
C, Cellular component (GO)
Term/pathway Description False discovery rate
GO:0015630 Microtubule cytoskeleton 2.43x10-5 
GO:0005819 Spindle 2.43x10-5 
GO:0044430 Cytoskeletal part 7.34x10-5 
GO:0005815 Microtubule organizing center 0.00033 
GO:0005829 Cytosol 0.00065 
D, KEGG pathways
Term/pathway Description False discovery rate
hsa04115 p53 signaling pathway 9.70x10-5 
hsa04114 Oocyte meiosis 0.00023 
hsa04110 Cell cycle 0.00023 
hsa04914 Progesterone-mediated oocyte maturation 0.0047 
hsa04120 Ubiquitin mediated proteolysis 0.0075
GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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that can be found in the literature is often not expressed using 
controlled vocabularies. This challenge was addressed by 
using DisGeNET, which is one of the most complete data-
bases publicly available that also includes data text mined 
from the literature. To overcome the limitation posed by the 
use of different terms, a broad set of terms to interrogate the 
database was used. Nevertheless, the information obtained 
might not be complete due to inherent limitations of the 
database (update cycle and/or incorrect capture of all the data 
present in publications). With regard to data mining tools, 
there is a limited availability of EC transcriptomics datasets, 
which constitutes an additional limitation, since it makes it 
difficult to validate candidate genes in independent datasets, 
which is feasible in other tumor types in which there is larger 
number of studies. Finally, while PPI networks are a useful 
tool for the integration of information from text/data mining 
and pathway databases, the selection of a small set of hub 
genes in network analysis may have excluded genes/proteins 
Figure 4. Kaplan-Meier analysis of selected hub genes. (A) Results of overall survival analysis for CDK1, KIF2C, UBE2C and TPX2 genes. (B) Results of 
recurrence-free survival analysis for CCNB2, CDCA8, CDC20, CDK1, KIF2C, RRM2, UBE2C and TPX2. P<0.05 was considered to indicate a statistically 
significant difference.
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within the network that could be potentially important for the 
phenotype of interest. However, due to the amount of DEGs 
and the complexity of the generated PPI, it was necessary 
to use a computer approach to select a small set of genes of 
interest. While the selected hub genes depicted a potential 
diagnostic/prognostic value for EC, further network analysis 
Figure 5. TPX2 expression analysis in EC cell lines and patient tumors. (A) RT-qPCR analysis of TPX2 in parental and ETV5 stable transfectants of Hec1a 
(left) and Ishikawa (right) EC cell lines (***P<0.001; Student's t‑test). (B) Western immunoblotting of TPX2 in total protein extracts of Hec1a and Hec1a‑ETV5, 
Ishikawa and Ishikawa‑ETV5 cells. (C) Fluorescent immunocytochemistry of TPX2 in Hec1a and Hec1a‑ETV5, Ishikawa and Ishikawa‑ETV5 cells. Nuclear 
staining was done with Hoechst 33342. Magnification, x600. RT‑qPCR analysis of TPX2 mRNA levels in (D) grade 1-2 (n=13) and 3 (n=14) tumors (*P=0.0494; 
Mann-Whitney U test), E) MI<50% (n=15) and MI>50% (n=11) tumors (**P=0.0051; Mann-Whitney U test), and (F) Low (n=11) and intermediate/high (n=22) 
risk tumors (*P=0.0374; Mann‑Whitney U test). EC, endometrial cancer; RT‑qPCR, reverse transcription‑quantitative PCR; TPX2, targeting protein for Xklp2; 
ETV5, ETS variant transcription factor 5; MI, myometrial invasion.
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could be performed to assess the relevance of other modules 
and sub-networks within the PPI presented as part of this work.
In conclusion, the use of an algorithm that combines a set 
of bioinformatics tools led to the identification of 10 genes, 
CCNB2, CDCA8, CDC20, CDK1, CENPF, KIF2C, RRM2, 
UBE2C, TOP2A and TPX2, associated with EC progression. 
In particular, to the best of our knowledge, this study was the 
first to identify TPX2 as an independent prognostic biomarker 
in stage I EC. Further validation studies in larger and inde-
pendent EC cohorts will contribute to confirm the prognostic 
value of TPX2 with the ultimate goal of proposing its use as a 
complement to current EC management.
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